Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KNSA Kiniksa Pharmaceuticals	$28.30 +2.1%	$24.95	$17.38 ▼ $30.69	$2.07B	0.06	514,758 shs	907,289 shs
MIRM Mirum Pharmaceuticals	$49.63 +1.2%	$43.06	$25.73 ▼ $54.23	$2.46B	0.95	510,918 shs	441,337 shs
NAMS NewAmsterdam Pharma	$20.21 -3.9%	$18.09	$14.06 ▼ $27.29	$2.27B	-0.03	676,605 shs	497,787 shs
VECT VectivBio	$16.85	$16.85	$4.25 ▼ $16.98	$573.24M	0.11	N/A	N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KNSA Kiniksa Pharmaceuticals	-8.24%	-6.06%	+8.32%	+22.64%	+46.49%
MIRM Mirum Pharmaceuticals	+1.16%	+9.79%	+8.28%	+10.70%	+81.56%
NAMS NewAmsterdam Pharma	+2.59%	+7.79%	+12.16%	-10.01%	+6.21%
VECT VectivBio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KNSA Kiniksa Pharmaceuticals	3.2721 of 5 stars	3.5	3.0	0.0	0.0	3.0	3.3	0.6
MIRM Mirum Pharmaceuticals	3.2152 of 5 stars	2.6	1.0	0.0	4.2	2.1	1.7	0.6
NAMS NewAmsterdam Pharma	2.9823 of 5 stars	3.5	2.0	0.0	0.0	2.6	5.0	0.0
VECT VectivBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KNSA Kiniksa Pharmaceuticals	3.00	Buy	$38.80	37.10% Upside
MIRM Mirum Pharmaceuticals	3.17	Buy	$60.73	22.36% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$43.00	112.77% Upside
VECT VectivBio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VECT, MIRM, KNSA, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/19/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$73.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$73.00 ➝ $77.00
5/9/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$74.00 ➝ $76.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
4/29/2025	KNSA Kiniksa Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/16/2025	KNSA Kiniksa Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$34.00 ➝ $34.00
4/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KNSA Kiniksa Pharmaceuticals	$481.17M	4.29	N/A	N/A	$6.23 per share	4.54
MIRM Mirum Pharmaceuticals	$379.25M	6.48	N/A	N/A	$5.33 per share	9.31
NAMS NewAmsterdam Pharma	$47.14M	48.13	N/A	N/A	$3.50 per share	5.77
VECT VectivBio	$27.34M	20.97	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KNSA Kiniksa Pharmaceuticals	$14.08M	-$0.25	N/A	113.20	N/A	-2.36%	-7.31%	-5.95%	7/22/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$163.41M	-$1.61	N/A	N/A	N/A	-31.69%	-41.22%	-14.81%	8/6/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$176.94M	-$1.88	N/A	N/A	N/A	N/A	N/A	N/A	8/6/2025 (Estimated)
VECT VectivBio	-$93.74M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest VECT, MIRM, KNSA, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KNSA Kiniksa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KNSA Kiniksa Pharmaceuticals	N/A	3.24	2.95
MIRM Mirum Pharmaceuticals	1.33	3.34	3.15
NAMS NewAmsterdam Pharma	N/A	10.61	10.61
VECT VectivBio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KNSA Kiniksa Pharmaceuticals	53.95%
MIRM Mirum Pharmaceuticals	N/A
NAMS NewAmsterdam Pharma	89.89%
VECT VectivBio	N/A

Insider Ownership

Company	Insider Ownership
KNSA Kiniksa Pharmaceuticals	54.57%
MIRM Mirum Pharmaceuticals	14.36%
NAMS NewAmsterdam Pharma	20.84%
VECT VectivBio	9.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KNSA Kiniksa Pharmaceuticals	220	72.97 million	32.80 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.54 million	37.03 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	74.37 million	Optionable
VECT VectivBio	30	34.02 million	N/A	No Data

VECT, MIRM, KNSA, and NAMS Headlines

Recent News About These Companies

Ironwood’s shares sink as FDA demands new trial for lead drug

April 15, 2025 | msn.com

A brain biotech launches with Roche’s spare parts

February 13, 2025 | biopharmadive.com

Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer

January 21, 2025 | markets.businessinsider.com

CDR-Life Appoints Sarah Holland, PhD, as Chief Business Officer

December 5, 2024 | finance.yahoo.com

Recent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBD

November 12, 2024 | gut.bmj.com

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight

September 23, 2024 | finance.yahoo.com

Etherio Group: 2024 CMI 25

September 21, 2024 | meetingsnet.com

Compare with VectivBio Holding AG (VECT)

May 29, 2024 | msn.com

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

May 15, 2024 | finance.yahoo.com

Vicore Pharma Holding: Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finanznachrichten.de

Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finance.yahoo.com

Short Bowel Syndrome Market by 2032: Forecast Report Estimates Significant Growth

April 5, 2024 | uk.finance.yahoo.com

FDA approves DMD treatment from Italfarmaco

March 31, 2024 | cen.acs.org

Pipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpoints

March 18, 2024 | msn.com

Ironwood Nabs Phase III Win, Still Sees Stock Nosedive

March 1, 2024 | biospace.com

Ironwood felled by mixed data in short bowel syndrome trial

March 1, 2024 | pharmaphorum.com

UPDATE 3-Ironwood's bowel disease drug meets main goal of late-stage study

March 1, 2024 | msn.com

Ironwood's bowel disease treatment meets main goal in late-stage trial

February 29, 2024 | reuters.com

Why Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?

February 29, 2024 | benzinga.com

Only two sleeps left until February 31!

February 29, 2024 | ft.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VECT, MIRM, KNSA, and NAMS Company Descriptions

Kiniksa Pharmaceuticals NASDAQ:KNSA

$28.30 +0.57 (+2.06%)

Closing price 04:00 PM Eastern

Extended Trading

$28.29 -0.01 (-0.04%)

As of 04:20 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Mirum Pharmaceuticals NASDAQ:MIRM

$49.63 +0.61 (+1.24%)

Closing price 04:00 PM Eastern

Extended Trading

$49.66 +0.02 (+0.05%)

As of 04:20 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

NewAmsterdam Pharma NASDAQ:NAMS

$20.21 -0.82 (-3.90%)

Closing price 04:00 PM Eastern

Extended Trading

$20.23 +0.02 (+0.10%)

As of 04:23 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

VectivBio NASDAQ:VECT

$16.85 0.00 (0.00%)

As of 06/10/2025

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time